M50054

Research use only, not for human use.

Apoptosis Inhibitor was a novel inhibitor of programmed cell death associate with caspase-3 inhibition.

Apoptosis Inhibitor was a novel inhibitor of programmed cell death associate with caspase-3 inhibition.(In Vitro):Apoptosis Inhibitor was identified as a novel inhibitor of apoptosis (programmed cell death) using an in vitro cell death assay system induced in human Fas-expressing WC8 cells by soluble human Fas ligand.

M50054 inhibits the caspase-3 activation by Etoposide in a dose-dependent manner. The IC50 value of M50054 against Etoposide-induced caspase-3 activation of U937 cells is 79 μg/mL. However, M50054 does not directly inhibit the enzymatic activity of caspase-3 at all concentrations up to 1000 μg/mL.M50054 (1-300 μg/mL) inhibits soluble human Fas ligand-induced cell death of human Fas-expressing WC8 cells in a dose-dependent manner, and the IC50 of 67 μg/mL.M50054 (30-300 μg/mL) inhibits the death of U937 cells induced by etoposide (10 μg/mL) in a dose-dependent manner, and the IC50 value of M50054 against Etoposide-induced cell death of U937 cells is 130 μg/mL. The IC50 value of M50054 against etoposide-induced DNA fragmentation of U937 cells was 54 μg/mL. Cell Proliferation Assay Cell Line:Human Fas-expressing WC8 cells Concentration:1, 3, 10, 30, 100, 300 μg/mL Incubation Time:Pre-incubated for 30 min Result:Inhibited soluble human Fas ligand-induced cell death of human Fas-expressing WC8 cells in a dose-dependent manner, and the IC50 of 67 μg/mL.

M50054 (10-300 mg/kg; oral administration 30 min before anti-Fas antibody injection) inhibits the elevation of alanine aminotransferase and aspartate aminotransferase in a dose-dependent manner.M50054 (topical treatment; given daily beginning on day 5 after birth and ending on day 14) significantly improves alopecia (hair loss) symptoms. Animal Model:Female BALB/c miceDosage:10, 30, 100 or 300 mg/kg Administration:Orally administered in a volume of 10 mL/kg Result:Inhibited the elevation of alanine aminotransferase and aspartate aminotransferase in a dose-dependent manner. Significantly improved these parameters at doses of 100 mg/kg and 300 mg/kg.Animal Model:Five-day-old SD rats Dosage:Administration:Topically applied to the head and back of 5-day-old rats once daily for 10 days Result:Alopecia scores significantly decreased throughout the entire observation period compared with the control group.

Apoptosis Inhibitor

Apoptosis

Caspase

CYP1A2|CYP2B6

——

——

54135-60-3

236.26

C13H16O4

>98% (HPLC)

——

O=C(CCC1)C(CC(C(CCC2)=O)C2=O)C1=O

——

(-20℃)

With Ice Pack

≥ 2 years